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ABSTRACT: Use of erythropoietin (EPO) is believed to be associated with adverse cardiovascular events, especially 
high blood pressure. Also, its illegal use in blood doping is thought to result in detrimental events both in humans and 
equines. To test this hypothesis, normal Wistar rats were treated with recombinant erythropoietin (rEPO @ 400 i.u/kg 
s.c) or normal saline one day apart for one week. Heart rate, systolic, diastolic, mean arterial pressure and blood count 
were determined. Rats were also observed for their behaviour during the study period. rEPO significantly (P<0.001) 
increased the erythrocyte count (RBC), haemoglobin (Hb), hematocrit (HCT) and platelet count (PLT) in comparison 
to control animals. Despite such an increase in hematocrit which in turn increases blood viscosity, the systemic blood 
pressure and heart rate did not differ between the groups. rEPO treatment did not cause any untoward behavioural 
change in animals. In conclusion, despite the profound effect on haematological parameters (especially hematocrit), 
rEPO was without any effect on blood pressure and heart rate and the hypothesis of short-term erythropoietin-induced 
alterations in cardiac parameters was not verified.
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Erythropoietin is a glycoprotein which is primarily secreted from the kidney. It acts on erythroid pro-
genitor cells in the bone marrow and stimulates their 
proliferation and differentiation (Jelkmann, 1992). 
Clinical applications of erythropoietin include severe 
anaemic hemodialysis patients, predialysis patients 
and patients in which anaemia is caused by a tumour 
or chemotherapy. In veterinary practice, rEPO is used 
in canine and feline patients suffering from non-re-
generative anaemia secondary to chronic renal failure 
(Mikiciuk et al., 1990; Giger, 1992; Cowgill et al., 
1998). Erythropoietin is illegally used in “blood dop-
ing” which is defined as an artificial increase in Hb/
hematocrit to enhance performance. Jelkmann (2000, 
2001) has reviewed the use of rEPO as an anti-anae-
mic and performance-enhancing drug. EPO is used by 
top endurance athletes such as long-distance runners 
and cyclists on a systemic basis (Pommering, 2007). 
Blood doping in racehorses is done to increase red 
blood cell count and thus enhancing oxygen-carrying 
capacity (Ungemach, 1985; Toutain, 2010). 
Therapy with rEPO is associated with the devel-
opment of high blood pressure or else its aggravation 
(Eschbach et al., 1989; Abraham et al., 1991). EPO 
therapy completely prevented the chronic renal failure 
(CRF)-associated anaemia but led to a marked rise in 
arterial blood pressure which began one week after the 
onset of EPO administration (Ni et al., 1998). It was 
also shown that in normotensive subjects there was a 
significant increase in resting mean arterial pressure 
(MAP) of +6mmHg (Lundby et al., 2007). Even it has 
been shown that rEPO produces a direct pressor effect 
on bilateral rat renal resistance vessels (Heidenreich 
et al., 1991) and human placental vessels (Resch et 
al., 2003). It was previously seen that rEPO impaired 
nitric oxide production and eNOS mRNA expression 
in pulmonary vasculature (Sultan et al., 2017).
In order to investigate the effect of recombinant 
erythropoietin on cardiovascular function and haema-
tology, normal rats were treated with rEPO or saline 
for one week. Heart rate, systolic blood pressure, di-
astolic blood pressure, mean arterial blood pressure 
and haematological parameters were determined. We 
hypothesised that erythropoietin induces excessive 
erythrocytosis which can cause increased blood vis-
cosity and increased systemic blood pressure. If this 
hypothesis was verified, more cautious use of erythro-
poietin is warranted. 
MATERIALS AND METHODS
Animals
Male Wistar rats (150-250g, 6-9 weeks of age) 
were acclimated for ten days before the experiments, 
placed in transparent polycarbonate cages and housed 
in an environmentally controlled room. They were 
kept under 12-h dark/light cycle and allowed free 
access to feed and water. A diet of following com-
position was provided to the rats: crude wheat 61 
%, crushed maize 30 %, wheat bran 7 %, common 
salt 1 % and mineral mixture 1 %. The rats were di-
vided into two groups of eight animals each. During 
the acclimatization, we measured the blood pressure 
of rats at least three times using the tail-cuff method 
(NIBP system, CODA, Kent Scientific Corporation, 
Torrington, CT, USA). We didn’t get any animal that 
was hypertensive thus ensuring that we are using nor-
motensive animals. According to “resource equation 
method” eight animals per group in our study is an ac-
ceptable sample size. The protocol was approved by 
the Institutional Animal Ethics Committee of Indian 
Veterinary Research Institute, Izzatnagar (Approval 
No. F1-53/2012-13/JDR).
Experimental design
Animals were divided into two groups i.e. Control 
group and Test group. The test group was adminis-
tered recombinant erythropoietin subcutaneously at 
400 IU/ kg (Sultan et al, 2017) on every other day (i.e. 
day1,3,5 and 7) for one week. In a similar fashion, the 
control group received normal saline. On the 8th day, 
the blood pressure was taken by tail-cuff plethysmog-
raphy. After measuring the blood pressure rats were 
anaesthetized with urethane (1.2 g/kg body weight 
i.p). Blood was collected from the retro-orbital plexus 
with the help of a capillary tube.
Blood pressure and heart rate
Initially, the rats were trained for ten days to make 
them friendly while taking blood pressure and heart 
rate. Systolic, diastolic and mean arterial pressures 
(MAP) were measured at the end of the treatment by 
tail-cuff plethysmography (IITC, mode 31, Woodland 
Hills, CA, USA) following established procedures. 
This method is analogous to sphygmomanometry in 
humans. Animals were adjusted to the experimental 
cages by bringing them into measuring chamber 3-4 
times before the start of the experiment for a period 
of 30–60 min. To measure blood pressure, a tubular 
inflatable cuff was placed around the base of the tail 
and a piezoelectric pulse detector was positioned dis-
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tal to the cuff. The systolic pressure was detected and 
subsequently recorded on a polygraph. Each measure-
ment was repeated at least three times and the mean of 
these values was used for further calculations. All the 
recordings and data analysis was done using a com-
puterized data acquisition system (BPMon, version 
1.32).
Haematological parameters
On the 8th day, blood was collected using EDTA 
containing vacutainers from retro-orbital plexus after 
proper anaesthesia. The collected blood was used for 
haematological assessment viz. haemoglobin (Hb), 
red blood cells (RBC), platelets (PLT), white blood 
cells (WBC), packed cell volume (PCV), mean cor-
puscular volume (MCV), mean corpuscular haemo-
globin (MCH) and mean corpuscular haemoglobin 
concentration (MCHC). These haematological pa-
rameters were determined by using automated haema-
tology analyser MEK-6450 (Nihon Kohden, Japan).
Statistical analysis
GraphPad Prism version 4.00 (San Diego, Califor-
nia, USA) software was used for statistical analysis. 
Student’s t-test was used in comparing data from two 
groups. For statistical comparisons, a P-value <0.01 
was considered significant. All data given are as 
means ± standard error of the mean (SEM).
RESULTS
Systolic (SAP), diastolic (DAP), mean arterial 
pressure (MAP) and heart rate were measured at the 
end of the treatment by tail cuff-plethysmography 
(IITC, mode 31, Woodland Hills, CA, USA). No sig-
nificant differences were observed in these parameters 
as shown in Table 1. Animals were also observed for 
any abnormal behaviour during the whole study and 
were found active and normal.
The effect of one-week EPO-treatment on various 
haematological parameters is presented in Table 2 and 
Figure 1. Erythropoietin significantly (p<0.001) in-
creased the erythrocyte count (RBC) 8.83 ± 0.27×106/
µl in comparison to control (7.44 ± 0.13×106/µl); he-
moglobin (Hb) 16.3 ± 0.38 g/dL in comparison to con-
trol (13.3±0.20 g/dL ); hematocrit (PCV/HCT) 51.2 ± 
1.09 % in comparison to control (40.1 ± 0.56 %) and 
platelet count (PLT) 903 ± 54×103/µl in comparison 
to control 669 ± 46×103/µl. There was no significant 
effect on leukocyte count (WBC), mean corpuscular 
volume (MCV) and mean corpuscular haemoglobin 
(MCH). There was a significant decrease in mean cor-
puscular haemoglobin concentration (MCHC).
Table 1. Effect of EPO-treatment on hemodynamic parameters. Data are presented as mean ± SEM; Pressure is in mmHg and Heart 
rate in Beats/min
Group Systolic pressure (mmHg) Diastolic pressure (mmHg) MAP (mmHg) Heart rate (BPM)
Control 146 ± 1.77 112 ± 1.82 122.8 ± 1.67 485.6 ± 10.68
rEPO-treated 146 ± 1.73 112 ± 2.13 122.9 ± 1.92 468.6 ± 9.46
Table 2. Effect of one-week rEPO-treatment on various haematological parameters. Data are presented as mean ± SEM, **P<0.001 
and ***P<0.0001 in comparison to control animals.
Parameter Control rEPO-treated
WBC (103/µl) 13 ± 1.2 15 ± 1.4
RBC (106/µl) 7.44 ± 0.13 8.83 ± 0.27***
Hb (g/dL) 13.3 ± 0.20 16.3 ± 0.38***
HCT (%) 40.1 ± 0.56 51.2 ± 1.09***
PLT (103/µl) 669 ± 46 903 ± 54**
MCV (fL) 53.9 ± 0.51 58.1 ± 0.83
MCH (pg) 17.9 ± 0.19 18.6 ± 0.26
MCHC (g/dl) 33.1 ± 0.22 31.9 ± 0.15***
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Figure 1: Bar diagrams showing the effect of EPO-treatment on various haematological parameters. **P<0.001 and ***P<0.0001 in 
comparison to control animals
DISCUSSION
An expanding increase in the clinical use of eryth-
ropoietin is witnessed. Apart from the clinical use, its 
illegitimate use has reached the point where various 
athletes have relied on its systemic use (Pommer-
ing, 2007). The annual prescription sales of EPO and 
erythropoiesis-stimulating agents (ESA) are expand-
ing (Steinbrook, 2007). The EPO doping is dangerous 
because of excessive erythropoiesis which can result 
in high blood viscosity, thromboembolism, and death. 
A meta-analysis showed an increased risk of venous 
thromboembolism and increased mortality rates after 
EPO administration (Bennet, 2008). The mechanisms 
of such events are not fully elucidated but EPO-in-
duced arterial hypertension is a leading candidate 
(Fishbane, 2007). A cause-effect relationship was hy-
pothesized in the present study.
We got profound changes in some haematological 
parameters in short term rEPO use in otherwise nor-
mal Wistar rats. Hematocrit was highly elevated from 
40% to 51% which is a profound increase. Haemo-
globin level jumped from 13g/dl to 16 g/dl within a 
week. We assumed that an increase in the hematocrit 
will result in increased blood viscosity and thus may 
result in hypertension since peripheral resistance is 
governed by blood viscosity apart from blood vessel 
diameter and total vessel length. Blood viscosity is a 
major determinant of cardiac work and tissue perfu-
sion (Levy et al., 2008). The more viscous the blood, 
the greater the resistance it encounters and the higher 
the blood pressure. A direct correlation between blood 
pressure and viscosity has been shown in both nor-
motensive and hypertensive subjects (Letcher et al., 
1981).
However, despite the increase in HCT the nor-
mal rats did not develop hypertension. No significant 
difference in blood pressure was found between the 
rEPO treated and control rats. It is unlikely that the 
dose of EPO in our study was too low to have any 
effect as we used a high dose over one week. Athletes 
associated with endurance sports possibly use EPO 
for short durations as in our study. EPO treatment 
was without effect on heart rate, blood pressure and 
behaviour except haematology variables in normal 
rats. The short-term changes described for these pa-
rameters in normal animals are therefore unlikely to 
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cause changes in cardiovascular function. Some au-
thors found no alteration of blood pressure, heart rate, 
or cardiac output, in transgenic mice over-expressing 
EPO (Vogel et al., 2003). They explain this by dis-
cussing an adaptive mechanism that involves the in-
creased activity of endothelial nitric oxide synthase 
and increased flexibility of transgenic erythrocytes.
CONCLUSION
Acute and high-dose administration of rEPO in-
stigated a profound effect on haematological param-
eters (especially hematocrit) but it was without any 
effect on heart rate or blood pressure. Our study does 
not provide evidence for pronounced cardiovascular 
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